Skip to main content
. 2013 Jul 5;288(33):23740–23750. doi: 10.1074/jbc.M113.487686

FIGURE 1.

FIGURE 1.

Effects of piceatannol on CDDP treatment in OVCA cell lines. A, reductions in cell viability caused by PCT (10 μm) in combination with CDDP treatment (10 μm, 24 h) in chemosensitive and chemoresistant OVCA. Piceatannol (10 μm) enhances the effects of CDDP (10 μm, 24 h) in OV2008, A2780s, and C13 cells. Although piceatannol did not confer any additional effects on CDDP treatment in p53-null SKOV-3, it enhanced the effects of CDDP (10 μm) in OVCAR-432, a chemosensitive p53-mutant cell line. B, time course study on the effects of PCT (10 μm) and CDDP (10 μm), alone and together, on cell viability of OV2008 cells over 48 h. C, effects of CDDP (5 μm), piceatannol (10 μm), and combined treatment on nuclear morphology in OV2008 cells after 24 h (stained with Hoechst 33258). Dual treatment significantly increases the severity of nuclear condensation and fragmentation in comparison to either agent alone. D, piceatannol treatment (2.5 μm, 24 h) induces a left shift in concentration-response curves for CDDP-induced apoptosis in chemosensitive OV2008 and A2780s. Both cell lines also exhibited a left shift in apoptotic response curves to piceatannol when in the presence of low CDDP concentration (5 μm). E, piceatannol induces a left shift in concentration-response curves for CDDP-induced apoptosis in chemoresistant C13* cells and induces sensitivity in combination with CDDP treatment (10 μm, 24 h) in chemoresistant p53-mutant A2780cp* at 10 μm concentration. *, p < 0.05; **, p < 0.01; ***, p < 0.001 versus respective dimethyl sulfoxide (DMSO) control (CTL).